DOCSLIB.ORG

HIV, HCV, TB: 2012 Pipeline Report, TAG and I-Base

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
HIV, HCV, TB: 2012 Pipeline Report, TAG and I-Base ABOUT HIV i-BASE HIV i-Base is a London-based HIV treatment activist organization. HIV i-Base works in the United Kingdom and internationally to ensure that people living with HIV are actively engaged in their own treatment and medical care and are included in policy discussions about HIV treatment recommendations and access. www.i-base.info ABOUT TAG The Treatment Action Group (TAG) is an independent AIDS research and policy think tank fighting for better treatment, a vaccine, and a cure for AIDS. TAG works to ensure that all people with HIV receive lifesaving treatment, care, and information. www.treatmentactiongroup.org 2012 PIPELINE REPORT HIV, HEPATITIS C VIRUS (HCV), AND TUBERCULOSIS (TB) DRUGS, DIAGNOSTICS, VACCINES, AND PREVENTIVE TECHNOLOGIES IN DEVELOPMENT By Polly Clayden, Simon Collins, Colleen Daniels, Nathan Geffen, Mark Harrington, Richard Jefferys, Coco Jervis, Karyn Kaplan, Erica Lessem, and Tracy Swan Edited by Andrea Benzacar JULY 2012 i-BASE/TREATMENT AcTION GROUP AUTHORS Polly Clayden, Simon Collins, Colleen Daniels, Nathan Geffen, Mark Harrington, Richard Jefferys, Coco Jervis, Karyn Kaplan, Erica Lessem, and Tracy Swan. EDITOR Andrea Benzacar DESIGNER Lei Chou ACKNOWLEDGMENTS Thanks to the TAG staff, board, and donors for supporting the production of the 2012 Pipeline Report. i-Base thanks the Monument Trust and UNITAID for support for this work. Polly Clayden thanks Shaffiq Essajee, Di Gibb, Andrew Hill, David Ripin, and Marco Vitoria. Richard Jefferys thanks Jennifer Woolley from Aeras and Erna Balk from the TuBerculosis Vaccine Initiative (TBVI). Colleen Daniels and Erica Lessem thank Lindsay McKenna. Treatment Action Group 261 Fifth Avenue Suite 2110 New York, NY 10016 Tel 212.253.7922 Fax 212.253.7923 www.treatmentactiongroup.org [email protected] ISBN 978-0-9837221-3-7 TABLE OF CONTENTS Introduction and Executive Summary 1 The Antiretroviral Pipeline 29 The Pediatric Antiretroviral Pipeline 61 Retrofitting for Purpose: Treatment Optimization 83 Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies 101 Hepatitis C Drug Development Goes from Pony Ride to Rocket Launch 137 Hepatitis C (HCV) Treatment Access: Spotlight on Thailand/Asia 185 The Tuberculosis Diagnostics Pipeline 193 The Tuberculosis Treatment Pipeline 217 The Tuberculosis Vaccine Pipeline 251 INTRODUCTION AND EXECUTIVE SUMMARY By Polly Clayden and Mark Harrington In nine countries, we enrolled 1763 couples in which one partner was HIV-1–positive and the other was HIV-1–negative; 54% of the subjects were from Africa, and 50% of infected partners were men. HIV-1–infected subjects with CD4 counts between 350 and 550 cells per cubic millimeter were randomly assigned in a 1:1 ratio to receive antiretroviral therapy either immediately (early therapy) or after a decline in the CD4 count or the onset of HIV-1–related symptoms (delayed therapy). The primary prevention end point was linked HIV-1 transmission in HIV-1–negative partners. The primary clinical end point was the earliest occurrence of pulmonary tuberculosis, severe bacterial infection, a World Health Organization stage 4 event, or death….As of February 21, 2011, a total of 39 HIV-1 transmissions were observed (incidence rate, 1.2 per 100 person-years; 95% confidence interval [CI], 0.9 to 1.7); of these, 28 were virologically linked to the infected partner (incidence rate, 0.9 per 100 person-years, 95% CI, 0.6 to 1.3). Of the 28 linked transmissions, only 1 occurred in the early-therapy group (hazard ratio, 0.04; 95% CI, 0.01 to 0.27; P<0.001). Subjects receiving early therapy had fewer treatment end points (hazard ratio, 0.59; 95% CI, 0.40 to 0.88; P=0.01). The early initiation of antiretroviral therapy reduced rates of sexual transmission of HIV-1 and clinical events, indicating both personal and public health benefits from such therapy. —MS Cohen et al.1 The fact that treatment of HIV-infected adults is also prevention gives us the wherewithal, even in the absence of an effective vaccine, to begin to control and ultimately end the AIDS pandemic....For the first time in the history of HIV/ AIDS, controlling and ending the pandemic are feasible; however, a truly global commitment...is essential. Major investments in implementation now will save even greater expenditures in the future; and in the meantime, countless lives can be saved. —AS Fauci2 The yearly cost of achievement of universal access to HIV prevention, treatment, care, and support by 2015 is estimated at no less than US$22 billion. Implementation of the new investment framework would avert 12.2 million new HIV infections and 7.4 million deaths from AIDS between 2011 and 2020 compared with continuation of present approaches, and result in 29.4 million life-years gained. The framework is cost effective at $1060 per life-year gained, and the additional investment proposed would be largely offset from savings in treatment costs alone. —B Schwartländer et al.3 1 2012 PIPELINE REPORT 2 INTRODUCTION AND EXECUTIVE SUMMARY Introduction Three papers published in the past year4,5,6 provide the scientific, public health, and policy framework for accelerating the response to the HIV pandemic such that within a few years the spread of HIV can be reversed, saving millions of lives and billions of dollars, using existing antiretroviral therapy (ART) introduced earlier and more broadly around the world. The only thing holding us back is the lack of economic and political leadership at the highest levels. Juxtaposed against a background of economic distress and political paralysis in the world’s rich countries not seen since the early 1930s, the abundance of promising advances documented in this year’s i-Base/TAG 2012 Pipeline Report may seen unattainably out of reach to many of the millions of people who need them most. It will be the task of the activists, implementers, policy makers, and scientists attending this year’s International AIDS Conference in Washington, D.C., to work together to turn the tide so that everyone who needs high-quality treatment and prevention interventions for the global HIV, hepatitis C virus (HCV), and tuberculosis (TB) pandemics receives them. Since the results of HPTN 052 were released last year,7 HIV prevention and treatment research have moved ever forward; the interventions that have saved over 7 million people’s lives since the advent of highly active antiretroviral therapy (HAART) in 1996 are also proving to be remarkably powerful as HIV prevention measures. The HPTN 052 study set a very high bar for performance, as the measured 96% reduction in HIV transmission was built upon a high-quality clinical trial design and implementation, good prevention practice in both arms, and evidently very high adherence rates. Although with less dramatic effect than HPTN 052, results of CAPRISA 0048 (which used tenofovir as a topical vaginal microbicide, like some other preexposure prophylaxis [PrEP] studies such as iPrEx9 which were released in the past two years, show that antiretrovirals can also offer protection when used by an HIV-negative partner, although the optimal use of these interventions is as yet uncertain. Table 1 shows the hierarchy of effect from clinical trial evidence using antiretrovirals for preventing sexual HIV transmission. But with all these studies, it is clear that adherence is required for treatment-as- prevention to work. Similarly, early studies in the HAART era showed that over 90% adherence was required for durable virological suppression among those taking treatment as treatment. 3 2012 PIPELINE REPORT TABLE 1. Clinical Trial Evidence Using Antiretrovirals for Preventing HIV Infection Study Effect Size % (CI) Treatment for prevention (HPTN 052) 96% (73–99) PrEP for serodiscordant couples (Partners PrEP) 73% (49–85) PrEP for heterosexuals (Botswana TDF 2) 63% (21–48) PrEP for men who have sex with men (iPrEx) 44% (15–63) Microbicide (CAPRISA 044 tenofovir gel) 39% (6–60) Source: Abdool Karim SS. CAPRISA 004 two years on: ten key lessons and their implications. Keynote address presented at: 2012 International Microbicides Conference; 2012 April 15; Sydney, Australia. Available from: http://www.microbicides2012.org/images/pdfs/m2012%20 -%20abdool%20karim%20-%20caprisa%20004%20lessons.pdf. (Accessed 2012 July 3) The potential contribution of these new discoveries to reduce the spread of HIV is directly threatened by today’s interlinked political and economic crises. Although a few administrative areas, such as the Canadian province of British Columbia and the city of San Francisco, California, have begun to provide universal offers of HIV treatment to all those referred to care, no country has yet started to fully implement these new interventions. The U.S. federal HIV treatment guidelines panel updated its recommendations in spring 2012 to recommend the universal offer of antiretroviral therapy (ART) to those with CD4 counts over 500 cells/mm3,10 but it is too soon to assess whether this change is affecting practice in the United States. The panel’s recommendation is based on disease stage, and its statement of the primary (therapeutic) and secondary (preventive) benefits of ART, and the evidence base for this recommendation is worth reading in full: The primary goal of antiretroviral therapy (ART) is to reduce HIV- associated morbidity and mortality. This goal is best accomplished by using effective ART to maximally inhibit HIV replication, as defined by achieving and maintaining plasma HIV RNA (viral load) below levels detectable by commercially available assays. Durable viral suppression improves immune function and quality of life, lowers the risk of both AIDS-defining and non-AIDS-defining complications, and prolongs life. Based on emerging evidence, additional benefits of ART include a reduction in HIV-associated inflammation and possibly its associated complications. The results of a randomized controlled trial and several observational cohort studies demonstrated that ART can reduce transmission of HIV.
Load more

Recommended publications
  • HIV-Infected Patients
    New Drugs for the Treatment-Experienced Patient Joseph Eron, md Associate Professor of Medicine and Director, Clinical Core unc Center for aids Research, University of North Carolina at Chapel Hill Summary by Tim Horn Edited by Jay Dobkin, md; Michael Saag, md reatment options for antiretro- humans by adenosine deaminase into D- Deeks and his colleagues in 1998 demon- viral-experienced patients leave a dioxolane guanine (dxg), a metabolite that strated a 1 log reduction in hiv-rna in hiv- lot to be desired. According to Dr. has potent activity against hiv and hbv. infected patients—more than 50% of whom Joe Eron, patients who have treat- According to in vitro data presented at were treatment-experienced—who received ment experience in all three classes the 3rd International Workshop on hiv tenofovir df 300 mg once daily as of currently available antiretrovi- Drug Resistance and Treatment Strategies, monotherapy for 28 days (Deeks, 1998). Trals have, at best, a 30% chance of re- held in June 1999, dapd was found to in- According to in vitro data presented by ducing their viral load to levels below 400 hibit wild-type and mutant isolates resistant Gilead’s Dr. Michael Miller at the recent copies/mL upon initiating a salvage regi- to azt (Retrovir) and 3TC (Borroto-Esoda, 4th International Resistance Workshop, the men. Cross-resistance within each class of 1999). The drug was also reported to be ac- resistance pattern for tenofovir df is simi- drugs, particularly the protease inhibitors tive against strains collected from patients lar to that of its chemical predecessor adefo- (pis) and non-nucleoside reverse tran- who have failed various nrti and nnrti vir, a compound no longer in development scriptase inhibitors (nnrtis), essentially combination therapies, including those for the treatment of hiv (Miller, 2000).
    [Show full text]
  • Download Article PDF/Slides
    Kan Lu, PharmD New Antiretrovirals for Based on a presentation at prn by Roy M. Gulick, md, mph the Treatment of HIV: Kan Lu, PharmD | Drug Development Fellow University of North Carolina School of Pharmacy Chapel Hill, North Carolina The View in 2006 Roy M. Gulick, md, mph Reprinted from The prn Notebook® | october 2006 | Dr. James F. Braun, Editor-in-Chief Director, Cornell Clinical Trials Unit | Associate Professor of Medicine, Meri D. Pozo, PhD, Managing Editor. Published in New York City by the Physicians’ Research Network, Inc.® Weill Medical College of Cornell University | New York, New York John Graham Brown, Executive Director. For further information and other articles available online, visit http://www.prn.org | All rights reserved. ©october 2006 substantial progress continues to be made in the arena of cokinetics and a long extracellular half-life of approximately 10 hours antiretroviral drug development. prn is again proud to present its annual (Zhu, 2003). During apricitabine’s development, a serious drug interac- review of the experimental agents to watch for in the coming months and tion with lamivudine (Epivir) was noted. Although the plasma years. This year’s review is based on a lecture by Dr. Roy M. Gulick, a long- concentrations of apricitabine were unaffected by coadministration of time friend of prn, and no stranger to the antiretroviral development lamivudine, the intracellular concentrations of apricitabine were reduced pipeline. by approximately sixfold. Additionally, the 50% inhibitory concentration To date, twenty-two antiretrovirals have been approved by the Food (ic50) of apricitabine against hiv with the M184V mutation was increased and Drug Administration (fda) for the treatment of hiv infection.
    [Show full text]
  • Cenicriviroc CSF Abstract Page 1 of 3 Title: Cerebrospinal Fluid Exposure
    Cenicriviroc CSF Abstract Title: Cerebrospinal fluid exposure of cenicriviroc in HIV-positive individuals with cognitive impairment Authors: Jasmini Alagaratnam1, Laura Else2, Sujan Dilly Penchala2, Elizabeth Challenger2, Ken Legg1, Claire Petersen1, Brynmor Jones3, Ranjababu Kulasegaram4, Star Seyedkazemi5, Eric Lefebvre5, Saye Khoo2 and Alan Winston1 1. Division of Infectious Diseases, Department of Medicine, Imperial College London, London W2 1PG 2. Department of Pharmacology, University of Liverpool, Liverpool L69 7SX, UK 3. Department of Radiology, Imperial College Healthcare NHS Trust, London W2 1NY 4. St. Thomas’ Hospital, London W6 8RP, UK 5. Clinical Development, Allergan plc, South San Francisco, USA Page 1 of 3 Cenicriviroc CSF Abstract Abstract Background: Cenicriviroc, a dual C-C chemokine receptor type 2 (CCR2) and type 5 (CCR5) antagonist, is a potential adjunctive therapy, along with antiretroviral therapy (ART), for the management of HIV-associated cognitive disorders. Materials and Methods: Virologically suppressed persons living with HIV (PLWH) with a clinical diagnosis of HIV-related cognitive impairment intensified ART with cenicriviroc once daily, dose dependent on current ART, for eight weeks. Subjects with current or previous use of CCR5 inhibitors were not eligible. We assessed cerebrospinal fluid (CSF) exposure of cenicriviroc and CSF albumin at week 8, and changes in cognitive function over 8 weeks. Cenicriviroc concentration was determined using reverse phase high-performance liquid chromatography (HPLC) with geometric mean (GM) and 95% confidence intervals (CI) calculated. The proposed cenicriviroc target concentration was above the 90% effective concentration (EC90) for cenicriviroc (0.17 ng/mL), with the lower limit of quantification (LLQ) 0.24 ng/mL taken as target concentration.
    [Show full text]
  • Download Article PDF/Slides
    New Antiretrovirals in Development: Reprinted from The PRN Notebook,™ june 2002. Dr. James F. Braun, Editor-in-Chief. Tim Horn, Executive Editor. Published in New York City by the Physicians’ Research Network, Inc.,® John Graham Brown, Executive Director. For further information and other articles The View in 2002 available online, visit http://www.PRN.org All rights reserved. © june 2002. Roy “Trip” Gulick, md, mph Associate Professor of Medicine, Weill Medical College of Cornell University Director, Cornell Clinical Trials Unit, New York, New York Summary by Tim Horn Edited by Scott Hammer, md espite the fact that 16 antiretro- tiviral activity of emtricitabine was estab- Preliminary results from two random- virals are approved for use in the lished, with total daily doses of 200 mg or ized studies—FTC-302 and FTC-303—were United States, there is an indis- more producing the greatest median viral reported by Dr. Charles van der Horst and putable need for new anti-hiv com- load suppression: 1.72-1.92 log. Based on his colleagues at the 8th croi, held in Feb- pounds that have potent and these data, a once-daily dose of 200 mg ruary 2001 in Chicago (van der Horst, durable efficacy profiles, unique re- was selected for further long-term clinical 2001). FTC-302 was a blinded comparison sistance patterns, patient-friendly dosing study. “This is what we’re looking forward of emtricitabine and lamivudine, both in schedules, and minimal toxicities. To pro- to with emtricitabine,” commented Dr. combination with stavudine (Zerit) and vide prn with a glimpse of drugs current- Gulick.
    [Show full text]
  • Interferon-Based and Interferon-Free New Treatment Options
    Interferon-based and interferon-free new treatment options White Nights of Hepatology St. Petersburg, 7. June 2013 Christoph Sarrazin Klinikum der J. W. Goethe-Universität Medizinische Klinik I Frankfurt am Main Mode of action of Interferons natural immunomodulatory effects IFN-stimulated gene activation Antiviral Apoptotic Immunomodulatory activity activity activity B-cell proliferation Reduced transcription Elevates apoptosis by CTL proliferation Reduced translation multiple mechanisms MHC upregulation Reduced RNA stability Augments NK activity Host-mediated effects are important for DAA combination therapy • Potency and additive effects • Prevention of resistance and viral breakthrough Different types of Interferons Type I Interferons Type III Interferons Broad receptor Receptors distribution distributed throughout various primarily in body tissues epithelial cells and hepatocytes Antiviral effects Antiviral effects Adverse events of Type I IFNs treatment Peg‐Intron • Flu-like symptoms PegIFN‐2a Type III IFNs Potentially fewer • Haematologic IFN omega Peg‐IFN‐ adverse events disorders IFN‐alfa‐2b XL lambda than with type I • Psychiatric Belerofon (Peg‐rIL‐29) interferons symptoms Albuferon Locteron Adapted from 1. Marcello T et al. Gastroenterology 2006;131:1887–98; 2. Muir AJ et al. 2009 AASLD. Abstract 1591; 3. O'Brien TR. Nat Genet. 2009;41:1048–50. PEG-Interferon alfa / Ribavirin Approval studies: efficacy Approval study (n=1530) Approval study (n=1121) Therapy: IFN vs. PEG-IFN alfa 2b Therapy: IFN vs. PEG-IFN alfa 2a 1,0/1,5µg/kgKG
    [Show full text]
  • UNO Template
    26 November 2013 Americas/United States Equity Research Biotechnology Global Biotech & Pharma: The HCV Revolution - Edition 2 Research Analysts COMMENT Ravi Mehrotra PhD 212 325 3487 [email protected] What Is The N Number: Keeping An Eye On Vamil Divan, MD 212 538 5394 Potential Longer Term Pricing Disruption [email protected] Koon Ching PhD ■ No pricing disruption expected in the near-term, but potential exists in 212 325 6286 the medium- to long-term. OK this is somewhat obvious, but bear with us: [email protected] Value/NPV = Price x Mkt Share x Mkt Size x Mkt Longevity. This is the Bruce Nudell PhD second note in our "The HCV Revolution" series. HCV is clearly a highly 212 325 9122 competitive therapeutic area with many players vying for their share of the [email protected] potentially >$15B/year HCV market. We previously addressed immediate- European Pharma Team 44 207 888 0304 term pricing of next-generation regimens, specifically for Sofosbuvir (LINK). [email protected] In this note, we simply highlight the potential number of competing all-oral, Ronak H. Shah, Pharm.D., CFA IFN-free regimens, and timing of key data, in HCV (Exhibits 1-7). The 212 325 9799 number of ultimate competitors has important implications for the HCV [email protected] market. In our view, in a HCV market with up to 4−5 players, we expect Lee Kalowski "normal drug rules" to apply: i.e. the order to market, overall clinical profile of 212 325 9683 drug, and commercial prowess will primarily dictate market share, with price [email protected] used as a tool but not in a "disruptive" way.
    [Show full text]
  • Recommendations on First and Second Line Antiretroviral Regimens
    POLICY BRIEF UPDATE OF RECOMMENDATIONS ON FIRST- AND SECOND-LINE ANTIRETROVIRAL REGIMENS JULY 2019 HIV TREATMENT WHO/CDS/HIV/19.15 © World Health Organization 2019 Some rights reserved. This work is available under the Creative Commons Attribution- NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/ licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. Update of recommendations on first- and second-line antiretroviral regimens. Geneva, Switzerland: World Health Organization; 2019 (WHO/CDS/HIV/19.15). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris. Sales, rights and licensing.
    [Show full text]
  • Nnrtis – MK1439 New Classes • Maturation Inhibitors, LEDGINS, Etc
    New Antiretrovirals and New Strategies Saye Khoo HIV Pharmacology Group Declaration of Interests •www.hiv-druginteractions.org & www.hep-druginteractions.org sponsorship from Janssen, ViiV, Abbott, Merck, BMS, Gilead, Boehringer, Vertex. Editorial content remains independent. •Research Grants: Merck, ViiV •Speakers bureau: Merck, Janssen, Abbott, Roche •Travel grants: Gilead, ViiV, BMS, Janssen •TaiLor trial (NIHR-funded) Antiretroviral Stewardship Myocardial Infarction Stroke Cancer Congnitive impairment Liver, renal etc Plan Now For Then • what to give ? • Minimise resistance • when to start ? • Minimise toxicity • how to manage ? • Preserve options • Normalise Immunity • Equip for future co-morbidity New Drugs, New Formulations, New Strategies Improvements on existing classes • TAF • dolutegravir and other integrases • new NNRTIs – MK1439 New Classes • Maturation inhibitors, LEDGINS, etc New Formulations • nanoformulations • mono- or dual therapy • LA injections or implants • targeting latent reservoirs New Strategies • NRTI-sparing, PI monotherapy • targeting latent reservoirs • targeting immune activation, cardiovascular risk • etc INSTIs NRTIs PIs NNRTIs Other Approved Dolutegravir Phase 3 TAF DRVc Doravirine TAF/FTC/EVGc (MK1349) Cenicriviroc RPV-LA BMS663068 Phase 2 GSK126744 Racivir ABC/3TC/DTG Amodoxovir TAF/FTC/DRVc Elvucitabine Doravirine (MK-1439) • Pharmacology – Potent - IC95 ~19 nM (50% human serum) – Once-daily dosing; T½ 10-16h – P450 metabolism (CYP3A4/5) • No significant inhibition/induction of CYP P450s • No significant
    [Show full text]
  • Emerging Therapies in NASH
    Emerging Therapies in NASH Stephen A Harrison, MD, FACP, FAASLD COL (ret.), USA, MC Visiting Professor of Hepatology Radcliffe Department of Medicine, University of Oxford Medical Director, Pinnacle Clinical Research President, Summit Clinical Research San Antonio, TX Disclosures • Scientific advisor or consultant for Akero, Alentis, Altimmune, Arrowhead, Axcella, Canfite, Cirius, CiVi Biopharma, Cymabay, Echosens, Fibronostics, Forest Labs, Galectin, Genfit, Gilead, Hepion, HistoIndex, Intercept, Madrigal, Medpace, Metacrine, NGM Bio, Northsea, Novartis, Novo Nordisk, PathAI, Poxel, Liminal, Ridgeline, Sagimet, Terns, Viking, 89 Bio. • Stock options: Akero, Cirius, Galectin, Genfit, Hepion, HistoIndex, PathAI, Metacrine, NGM Bio, Northsea. • Grant/Research support: Akero, Axcella, BMS, Cirius, CiVi Biopharma, Conatus, Cymabay, Enyo, Galectin, Genentech, Genfit, Gilead, Hepion, Hightide, Intercept, Madrigal, Metacrine, NGM Bio, Novartis, Novo Nordisk, Northsea, Pfizer,Sagimet, Viking. Goals of NASH Treatment • Improve metabolic abnormalities • Decrease inflammation • Prevent/arrest/reverse liver fibrosis – AASLD recommends pharmacological treatments aimed primarily at improving liver disease should generally be limited to those with biopsy-proven NASH and fibrosis • Prevent advanced liver disease, liver failure, liver cancer and related outcomes • Systemic outcomes (eventually) Chalasani N et al. Hepatology. 2018;67:328-35. Lifestyle Recommendations for Treating NASH Caloric intake Weight loss Exercise No heavy alcohol reduction of 3%
    [Show full text]
  • Design and Evaluation of 5•²-O-Dicarboxylic And
    University of Rhode Island DigitalCommons@URI Open Access Master's Theses 2014 DESIGN AND EVALUATION OF 5′-O-DICARBOXYLIC AND POLYARGININE FATTY ACYL DERIVATIVES OF ANTI-HIV NUCLEOSIDES Bhanu Priya Pemmaraju Venkata University of Rhode Island, [email protected] Follow this and additional works at: https://digitalcommons.uri.edu/theses Recommended Citation Pemmaraju Venkata, Bhanu Priya, "DESIGN AND EVALUATION OF 5′-O-DICARBOXYLIC AND POLYARGININE FATTY ACYL DERIVATIVES OF ANTI-HIV NUCLEOSIDES" (2014). Open Access Master's Theses. Paper 474. https://digitalcommons.uri.edu/theses/474 This Thesis is brought to you for free and open access by DigitalCommons@URI. It has been accepted for inclusion in Open Access Master's Theses by an authorized administrator of DigitalCommons@URI. For more information, please contact [email protected]. DESIGN AND EVALUATION OF 5′-O- DICARBOXYLIC AND POLYARGININE FATTY ACYL DERIVATIVES OF ANTI-HIV NUCLEOSIDES BY BHANU PRIYA, PEMMARAJU VENKATA A THESIS SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE MASTER’S DEGREE IN BIOMEDICAL AND PHARMACEUTICAL SCIENCES UNIVERSITY OF RHODE ISLAND 2014 MASTER OF SCIENCE THESIS OF BHANU PRIYA, PEMMARAJU VENKATA APPROVED: Thesis Committee: Major Professor Keykavous Parang Roberta King Stephen Kogut Geoffrey D. Bothun Nasser H. Zawia DEAN OF THE GRADUATE SCHOOL UNIVERSITY OF RHODE ISLAND 2014 ABSTRACT 2′,3′-Dideoxynucleoside (ddNs) analogs are the most widely used anti-HIV drugs in the market. Even though these drugs display very potent activities, they have a number of limitations when are used as therapeutic agents. The primary problem associated with ddNs is significant toxicity, such as neuropathy and bone marrow suppression.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2016/0058872 A1 Crew Et Al
    US 2016.0058872A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0058872 A1 Crew et al. (43) Pub. Date: Mar. 3, 2016 (54) IMIDE-BASED MODULATORS OF A613 L/426 (2006.01) PROTEOLYSIS AND ASSOCATED METHODS A 6LX3 L/505 (2006.01) OF USE A613 L/454 (2006.01) A613 L/55 (2006.01) (71) Applicant: Arvinas, Inc., New Haven, CT (US) C07D40 L/4 (2006.01) A6II 45/06 (2006.01) (72) Inventors: Andrew P. Crew, Guilford, CT (US); (52) U.S. Cl. Craig Crews, New Haven, CT (US), CPC ............ A61K 47/481 (2013.01); C07D401/14 Hanging Dong, Madison, CT (US); Jing (2013.01); C07D 495/14 (2013.01); C07D Wang, Milford, CT (US); Yimin Qian, 417/14 (2013.01); A61K 45/06 (2013.01); Plainsboro, NJ (US); Kam Siu Milford, A6 IK3I/505 (2013.01); A61 K3I/454 CT (US); Meizhong Jin, East Northport, (2013.01); A61 K3I/551 (2013.01); A61 K NY (US) 3 1/426 (2013.01) (21) Appl. No.: 14/792,414 (57) ABSTRACT (22) Filed: Jul. 6, 2015 The description relates to imide-based compounds, including Related U.S. Application Data bifunctional compounds comprising the same, which find utility as modulators of targeted ubiquitination, especially (63) Continuation-in-part of application No. 14/686.640, inhibitors of a variety of polypeptides and other proteins filed on Apr. 14, 2015. which are degraded and/or otherwise inhibited by bifunc (60) Provisional application No. 61/979,351, filed on Apr. tional compounds according to the present invention. In par 14, 2014, provisional application No.
    [Show full text]
  • HIV/AIDS Technologies: a Review of Progress to Date and Current Prospects
    Working Paper No.6 HIV/AIDS Technologies: A review of progress to date and current prospects COMMISSIONED BY: aids2031 Science and Technology Working Group AUTHORED BY: KEITH ALCORN NAM Publications Disclaimer: The views expressed in this paper are those of the author(s) and do not necessarily reflect the official policy, position, or opinions of the wider aids2031 initiative or partner organizations aids2031 Science and Technology working group A review of progress to date and current prospects October 2008 Acronyms 3TC lamivudine ANRS Agènce Nationale de Récherche sur la Sida ART Antiretroviral therapy ARV Antiretroviral AZT azidothymidine or zidovudine bDNA branched DNA CDC US Centers for Disease Control CHER Children with HIV Early Antiretroviral therapy (study) CTL Cytotoxic T-lymphocyte D4T stavudine DSMB Data and Safety Monitoring Board EFV Efavirenz ELISA Enzyme Linked Immunosorbent Assay FDC Fixed-dose combination FTC Emtricitabine HAART Highly Active Antiretroviral Therapy HBAC Home-based AIDS care HCV Hepatitis C virus HPTN HIV Prevention Trials Network HSV-2 Herpes simplex virus type 2 IAVI International AIDS Vaccine Initiative IL-2 Interleukin-2 LED Light-emitting diode LPV/r Lopinavir/ritonavir MIRA Methods for Improving Reproductive Health in Africa trial MSF Médecins sans Frontières MSM Men who have sex with men MVA Modified vaccinia Ankara NIH US National Institutes of Health NRTI Nucleoside reverse transcriptase inhibitor NNRTI Non-nucleoside reverse transcriptase inhibitor OBT Optimised background therapy PCR Polymerase
    [Show full text]